Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback